Genenta Science (GNTA) Expected to Release Quarterly Earnings on Wednesday

Genenta Science (NASDAQ:GNTA) is anticipated to announce its resultson Wednesday, September 2nd. Analysts expect Genenta Science to announce earnings of ($0.2741) per share for the quarter.

Genenta Science Stock Performance

NASDAQ GNTA opened at $1.00 on Monday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 14.16 and a current ratio of 14.16. Genenta Science has a 12 month low of $0.55 and a 12 month high of $10.00. The company’s 50 day moving average is $1.46 and its two-hundred day moving average is $1.12.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Genenta Science from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Genenta Science presently has a consensus rating of “Sell”.

Institutional Trading of Genenta Science

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC bought a new position in Genenta Science in the 3rd quarter worth approximately $41,000. SmartHarvest Portfolios LLC bought a new stake in shares of Genenta Science during the fourth quarter valued at approximately $26,000. Alyeska Investment Group L.P. purchased a new position in shares of Genenta Science in the fourth quarter worth $328,000. Norges Bank purchased a new position in shares of Genenta Science in the fourth quarter worth $337,000. Finally, Weiss Asset Management LP bought a new position in shares of Genenta Science during the fourth quarter worth $480,000. Institutional investors own 15.13% of the company’s stock.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.